{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:08:33Z","timestamp":1785553713731,"version":"3.56.0"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Guselkumab is the first approved human IgG1\u03bb monoclonal antibody selectively targeting the p19 subunit of IL23. Its effectiveness and safety were widely reported by clinical trials. However, these results must be confirmed in real life since its safety deals with more complicated subjects with respect to trials. Currently, real-life data on the use of guselkumab following treatment failure with ustekinumab are limited, and existing studies usually show a small cohort and\/or a reduced follow-up period. In this context, the aim of our study was to evaluate the use of guselkumab in patients who previously did not respond to ustekinumab after up to 3 years of treatment. Methods: A multicenter retrospective study was performed. The study enrolled patients affected by moderate-to-severe plaque psoriasis undergoing treatment with guselkumab who were attending the Psoriasis Center of nine different centers in the Campania region of Italy. Demographic and clinical features were collected for each patient at baseline. Moreover, data on psoriasis severity and adverse events (AEs) were collected at each follow-up visit (week (W)16-W36-W52-W104-W156). Results: A total of 112 patients (70 male, 62.5%; mean age 54.8 \u00b1 11.7 years old) were enrolled. Of these, 48 (42.9%), 34 (30.4%), and 16 (14.3%) reached 1, 2, and 3 years, respectively, of follow-up under guselkumab. A statistically significant clinical improvement was observed since W16, and sustained effectiveness was reported at each timepoint up to W156. No serious AEs were collected. Moreover, a sub analysis on the body mass index, involvement of difficult-to-treat areas, and presence of psoriatic arthritis (PsA) showed that the presence of PsA or palmoplantar psoriasis was associated with a reduced clinical improvement at W16 and W36, without differences from W52. In contrast, the efficacy of guselkumab does not seem to be affected by the BMI, involvement of fingernails, or location in the genital or scalp area. Conclusions: To sum up, our long-term real-life multicenter retrospective study confirmed the efficacy and safety of guselkumab following ustekinumab discontinuation up to 156 weeks of treatment.<\/jats:p>","DOI":"10.3390\/jcm13092552","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T08:18:27Z","timestamp":1714119507000},"page":"2552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"first","affiliation":[{"name":"Section of Dermatology\u2013Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania L. Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Caccavale","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania L. Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-216X","authenticated-orcid":false,"given":"Sara","family":"Cacciapuoti","sequence":"additional","affiliation":[{"name":"Section of Dermatology\u2013Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, San Gennaro Hospital, 80136 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania L. Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Di Costanzo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84084 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Manzo","sequence":"additional","affiliation":[{"name":"U.O.C. Dermatologia, ASL Salerno Ospedale Tortora Pagani, 84121 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Marino","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fatebenefratelli Hospital, 20121 Benevento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Valentina","family":"Puca","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermosurgery, AOSG San Giuseppe Moscati, 83100 Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Romano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, AORN \u201cA. Cardarelli\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriele","family":"Sarno","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermosurgery, AOSG San Giuseppe Moscati, 83100 Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genoveffa","family":"Scotto di Luzio","sequence":"additional","affiliation":[{"name":"Sant\u2019Anna and San Sebastiano Hospital, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84084 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: What is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert. Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kamata, M., and Tada, Y. (2020). Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051690"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13543784.2023.2219387","article-title":"The holistic approach to psoriasis patients with comorbidities: The role of investigational drugs","volume":"32","author":"Camela","year":"2023","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","article-title":"New frontiers in personalized medicine in psoriasis","volume":"22","author":"Camela","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14712598.2018.1445223","article-title":"Guselkumab for the treatment of psoriasis","volume":"18","author":"Megna","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1111\/ijd.15644","article-title":"Real-world experience versus clinical trials: Pros and cons in psoriasis therapy evaluation","volume":"61","author":"Cinelli","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"adv00032","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and Treatment: Past, Present and Future Aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Klisic, A., Bakic, M., and Karanikolic, V. (2023). Comparative Analysis of Redox Homeostasis Biomarkers in Patients with Psoriasis and Atopic Dermatitis. Antioxidants, 12.","DOI":"10.3390\/antiox12101875"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tokuyama, M., and Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207488"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13555-023-01092-x","article-title":"Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)","volume":"14","author":"Reich","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_20","first-page":"e15757","article-title":"Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life","volume":"35","author":"Rivera","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1111\/jdv.16511","article-title":"Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: A retrospective multicenter study","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/jdv.18913","article-title":"Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study\u2014IL PSO (ITALIAN LANDSCAPE PSORIASIS)","volume":"37","author":"Gargiulo","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e14673","DOI":"10.1111\/dth.14673","article-title":"Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and\/or anti-interleukin-17 treatment: A real-life 52-week retrospective study","volume":"34","author":"Ruggiero","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_24","first-page":"2560","article-title":"Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: A 52-week real-life study","volume":"33","author":"Megna","year":"2022","journal-title":"J. DermatologTreat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: Results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J. Dermatolog Treat."},{"key":"ref_26","first-page":"e15760","article-title":"Guselkumab as a switching strategy after anti-TNF\u03b1, anti-IL17, or anti-IL12\/23 therapies in moderate-to-severe psoriasis","volume":"35","author":"Chinchay","year":"2022","journal-title":"Dermatol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:33:52Z","timestamp":1760106832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/9\/2552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13092552"],"URL":"https:\/\/doi.org\/10.3390\/jcm13092552","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}